DiaMedica Therapeutics Inc. (DMAC) Social Stream
DIAMEDICA THERAPEUTICS INC (DMAC) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering DIAMEDICA THERAPEUTICS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-01 | 3 | $24 | $11 | $18.666 | $2.86 | 552.66% |
| 2021-11-12 | 3 | $24 | $11 | $17.333 | $2.86 | 506.05% |
| 2022-03-18 | 2 | $24 | $11 | $16.666 | $2.86 | 482.73% |
| 2022-04-08 | 2 | $24 | $6 | $15 | $2.86 | 424.48% |
| 2022-05-05 | 3 | $16 | $6 | $12.333 | $2.86 | 331.22% |
| 2022-07-07 | 3 | $12 | $8 | $10 | $2.86 | 249.65% |
| 2022-08-11 | 4 | $16 | $8 | $12 | $2.86 | 319.58% |
| 2023-06-22 | 3 | $12 | $7 | $9 | $2.86 | 214.69% |
| 2023-11-14 | 2 | $7 | $7 | $7 | $2.86 | 144.76% |
The Trend in the Analyst Price Target
Over the past 33 months, DMAC's average price target has gone down $9.2.
DMAC reports an average of 126.6% for its upside potential over the past 145 days.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-06-22 | 1 | 7 | 7 | 7 | 4.05 | 72.84% |
| 2023-06-22 | 3 | 12 | 7 | 9 | 4.05 | 122.22% |
| 2023-06-22 | 3 | 7 | 7 | 7 | 4.05 | 72.84% |
| 2023-06-22 | 1 | 12 | 7 | 9 | 4.05 | 122.22% |
| 2023-11-14 | 2 | 7 | 7 | 7 | 2.50 | 180% |
DMAC Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 1 | 0 | 0 | 0 | 0 | 1 |
The Trend in the Broker Recommendations
DMAC's average broker recommendation rating improved by 0 over the prior 41 months.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- DMAC has a greater number of analysts covering the stock than 103.06% of all US stocks.
- DMAC has a higher upside potential (average analyst target price relative to current price) than 1355.69% of all US stocks.
- To contextualize these metrics, consider that out of all US stocks, DIAMEDICA THERAPEUTICS INC's average analyst price target is higher than 215.57% of them.
- In the context of stocks in the micro market cap category, DIAMEDICA THERAPEUTICS INC's variance in analysts' estimates is lower than -862.56% of them.
In the Pharmaceutical Products industry, AGE, ETON, and EQ are the three stocks most similar to DIAMEDICA THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Make investment decisions regarding DMAC using the data that counts. Try POWR Ratings for free.